Somayeh ebadollahzadeh - Department of Biology, Higher Education Institute of Rab rashid, Tabriz,
parisa kangari - Department of Biology, Higher Education Institute of Rab rashid, Tabriz
Sultan ali mahboob - Department of Biology, Higher Education Institute of Rab rashid, Tabriz
Ali reza nourazarian - Research Center for Pharmaceutical Nanotechnology, ۲Department of Clinical Biochemistry andClinical Laboratory, Faculty of

Breast cancer (BC) is the second most common malignant neoplasms after lung cancer in the world, with approximately 410 000 cases of death of infected with this disease annually.In recent years, different studies have described the role of ischemia modified albumin (IMA) as a new markerfor diseases related to inflammation. The aim of this study was to evaluate the levels of the novel marker ischemia modified albumin(IMA) in patients with breast cancer. Materials and Methods: Thirty eight female patients with BC (mean age, 40/78±./847 years) and thirty eight age-sex matched healthy persons(mean age 39/61±./926years) were included in this study. After samples collection, the serum was separated, and after separating the serum they kept in -70 ° C until of day examination. In this study IMA serum levels were measured by chemical methods.Results: In this study,levels of the serum IMA were significantly higher in patients with BC compared to controls. Discussion: According to the result of evaluation there is a direct relationship between the level of serum IMA and breast cancer. IMA is indicated a marker of ischemia and oxidative stress originating as a consequence of tissue hypoxia. Ima changes have been seen in a variety of diseases.

Breast cancer, Ischemia modified albumin(IMA), oxidative stress